Journal
EUROPEAN JOURNAL OF HAEMATOLOGY
Volume 107, Issue 6, Pages 617-623Publisher
WILEY
DOI: 10.1111/ejh.13699
Keywords
BCR-ABL Positive; chronic myelogenous leukemia; clinical trial; dasatinib; interferon-alpha
Categories
Funding
- BMS
- MSD
Ask authors/readers for more resources
Adding low dose PegIFN-alpha to DAS in the treatment of CML-CP patients has shown good long-term efficacy without increased toxicity, with the majority of patients reaching MMR at some point during the study. This combination therapy may be a promising approach for achieving treatment-free remission in CML-CP.
Objectives Treatment-free remission (TFR) has emerged as a treatment goal in chronic myeloid leukemia in the chronic phase (CML-CP). Attempts to increase proportion of patients achieving TFR include combination of tyrosine kinase inhibitors (TKI) and other drugs. Interferon-alpha in addition to TKI has shown promising efficacy but with dose-dependent toxicity and discontinuations. NordCML007 was initiated to study the efficacy and safety of low dose pegylated IFN-alpha (PegIFN-alpha) in combination with dasatinib (DAS) in CML-CP. Methods Forty patients with newly diagnosed CML-CP were given DAS upfront. After month 3 (M3) 15 mu g/wk of PegIFN-alpha was added and increased to 25 mu g/wk from M7 until M15. DAS treatment was continued and adverse events and BCR-ABL1 qRT-PCR values were reported yearly after M24. Results from M1 to M18 have previously been published, and here we present long-term data. Results After 5 years of follow-up, there were no suspected unexpected serious adverse reactions, no increase in serosal effusions, no disease progressions and no CML-related deaths. Rates of MR3.0 (MMR), MR4.0 and MR4.5 were 84.6%, 64.1% and 51.3% respectively at M60, and 95% of patients reached MMR at some point during the study. Conclusion Initial addition of PegIFN-alpha to DAS shows good long-term efficacy without increased toxicity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available